Clinical trials: Rituximab
Rheumatoid Arthritis
Long-Term Efficacy and Safety of CT-P10 in Patients With RA
This is an open-label, single-arm, multicenter, efficacy, and safety maintenance study of the Phase 1 Study CT-P10 1.1. This study is designed to assess the long-term efficacy and safety of CT-P10 co-administered with MTX and…
- Trial name
- NCT01873443
- Testing
- Rituximab, MTX, folic acid
- Where
- South Korea
- Volunteers
- 87 people
- Sponsor
- Celltrion
Chronic Lymphocytic Leukemia
An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia
This study will examine the effectiveness of MabThera therapy added to a standard chemotherapy regimen for the treatment of previously untreated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02080884
- Where
- 15 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
B-Cell Non-Hodgkin Lymphoma
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- NCT05201248
- Testing
- Epcoritamab, Cyclophosphamide, Rituximab
- Where
- 18 sites in China
- Volunteers
- 49 people
- Sponsor
- Genmab
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.
This single arm study will evaluate the efficacy and safety of MabThera in patients with active rheumatoid arthritis whose current treatment with one or more TNF blocker had produced an inadequate response.
- Trial name
- NCT00424502
- Testing
- rituximab [MabThera/Rituxan], Methotrexate
- Where
- 3 sites in Hungary
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Relapsed Lymphoma
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
This is a phase 1, open-label, dose-escalation study of fimepinostat (CUDC-907) in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL) with or without MYC and BCL2…
- Conditions
- Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma
- Trial name
- NCT01742988
- Testing
- fimepinostat, Rituximab, venetoclax
- Where
- 11 sites in United States
- Volunteers
- 106 people
- Sponsor
- Curis, Inc.
Diffuse Large B Cell Lymphoma
A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients
The primary objective of the study is to assess the efficiency of SCT400 plus CHOP versus Rituximab plus CHOP in untreated CD20-positive DLBCL Patients.
- Trial name
- NCT02772822
- Testing
- SCT400 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Lymphocytic Leukemia, Chronic
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
This multi-center, randomized study compared the efficacy and safety of MabThera (rituximab) in combination with either fludarabine and cyclophosphamide or with chlorambucil in participants with previously untreated B-cell…
- Trial name
- NCT01283386
- Testing
- Chlorambucil, Cyclophosphamide, Fludarabine
- Where
- 8 sites in Russia
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Non-Hodgkin
BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
This is a Phase III, multicenter, randomized, double-blind, parallel-arm, active comparator trial to evaluate BI 695500 versus rituximab as a first-line immunotherapy treatment in patients with LTBFL.
- Trial name
- NCT02417129
- Testing
- Rituximab, BI 695500
- Where
- 21 sites in United States, Austria and 4 more
- Volunteers
- 2 people
- Sponsor
- Boehringer Ingelheim
Chronic Lymphocytic Leukemia
A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)
This Phase 3, randomized, double-blind, placebo-controlled study is to evaluate the effect of idelalisib in combination with rituximab on the onset, magnitude, and duration of tumor control in participants previously treated for…
- Trial name
- NCT01539512
- Testing
- Idelalisib, Rituximab
- Where
- 72 sites in United States, France and 3 more
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
Lymphoma, Large B-Cell, Diffuse
A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma
This multicenter, randomized, open label parallel-group study will evaluate the efficacy and safety of subcutaneous versus intravenous MabThera/Rituxan (rituximab) in combination with CHOP chemotherapy in patients with previously…
- Trial name
- NCT01649856
- Testing
- CHOP, rituximab [MabThera/Rituxan]
- Where
- 186 sites in Algeria, Argentina and 25 more
- Volunteers
- 572 people
- Sponsor
- Hoffmann-La Roche
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
Diffuse Large B-Cell Lymphoma (DLBCL)
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
This is an open-label, randomized controlled, multicenter Phase II clinical study primarily evaluating the efficacy and safety of Rocbrutinib monotherapy compared to the investigator's choice of BR/R2 regimen in patients with…
- Trial name
- NCT07189065
- Testing
- Rocbrutinib, Bendamustine, Rituximab
- Where
- 41 sites in China
- Volunteers
- 150 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Lymphoma, B-cell, Diffuse
Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma
For SyB L-0501RI administered by an intravenous rapid infusion in combination with rituximab, the safety will be investigated in previously untreated patients with low-grade B-cell non-Hodgkin's lymphoma (Lg-B-NHL) or mantle cell…
- Trial name
- NCT03900377
- Testing
- SyB L-0501RI
- Where
- 14 sites in Japan
- Volunteers
- 37 people
- Sponsor
- SymBio Pharmaceuticals
Lymphoma, Mantle-Cell
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
The purpose of this study is to provide continued access to treatment for participants who continue to benefit from treatment.
- Trial name
- VEGA (NCT05564052)
- Testing
- Ibrutinib, Lenalidomide, Rituximab
- Where
- 66 sites in Brazil, Czechia and 11 more
- Volunteers
- 36 people
- Sponsor
- Janssen Research & Development, LLC
Malignancy, Non-hodgkin Lymphoma
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with…
- Conditions
- Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer
- Trial name
- NCT03997968
- Testing
- CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine
- Where
- 16 sites in United States
- Volunteers
- 169 people
- Sponsor
- Cyteir Therapeutics, Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
The purpose of this study is to compare the efficacy and safety of liso-cel vs Investigator's Choice options (idelalisib + rituximab or bendamustine + rituximab) in adult participants with R/R CLL or SLL, whose disease has failed…
- Trial name
- NCT06205290
- Testing
- Liso-cel, Idelalisib, Rituximab
- Where
- 48 sites in United States, Austria and 9 more
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Diffuse Large B-Cell Lymphoma
An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma
This multicenter, observational study will evaluate the correlation between clinical and biological factors and International Prognostic Index (IPI) as prognostic factors in patients with diffuse large B-cell lymphoma receiving…
- Trial name
- NCT01724294
- Where
- Romania
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
Diffuse, Large B-Cell, Lymphoma
A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients
The purpose of this study is to comparing the Efficacy and Safety between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients.
- Trial name
- NCT02867566
- Testing
- IBI301 plus CHOP, Rituximab plus CHOP
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Chronic Lymphocytic Leukemia
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia
This is an open-label Phase 2 study to evaluate the safety and efficay of AT-101 in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
- Trial name
- NCT00286780
- Testing
- AT-101
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Ascenta Therapeutics
Primary Membranous Nephropathy
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial.
- Trial name
- NCT05696613
- Testing
- SNP-ACTH (1-39) Gel, Rituximab
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 148 people
- Sponsor
- Cerium Pharmaceuticals, Inc.